Thymosin alpha-1 treatment for COVID-19 in 78 patients revealed significant gender differences: men showed higher inflammatory markers (CRP, IL-6) but lower PCT after treatment, while women had different lymphocyte responses — explaining male COVID-19 vulnerability.
Gender matters for Tα1Men and women showed significantly different inflammatory marker and lymphocyte responses to thymosin alpha-1 treatment for COVID-19 — immune therapy may need sex-specific optimization
What the researchers found
Tα1 treatment (1.6 mg SC × 15 days) in 78 COVID-19 patients showed gender-dependent immune responses: males had higher CRP and IL-6 but lower PCT post-treatment. Significant variability in lymphocyte subpopulations between Tα1-treated males and females.
Why it matters
Understanding sex-specific immune responses to COVID-19 treatment could improve outcomes. If Tα1 works differently in men and women, dosing and treatment duration might need gender-specific optimization.
The numbers in context
N=127; 78 treated, 49 controls; 1.6 mg Tα1 subcutaneous; 15-day treatment; 42.52% female
How the study worked
Retrospective clinical study. 127 COVID-19 patients (42.52% female), Wuhan Union Hospital. 78 received Tα1 1.6mg SC × 15 days + supportive care. 49 controls received supportive care only. CRP, PCT, IL-6, lymphocyte subpopulations, and symptom analysis by gender.
Who was studied
COVID-19 positive adults (42.52% female) at Wuhan Union Hospital
What this study cannot tell us
Retrospective study without randomization blinding. Small sample (127 total). Single center in Wuhan during early pandemic. Standard care may have varied. Gender as a binary variable may oversimplify biological sex differences. Mortality and clinical outcome data limited.
How to read the evidence
Low-to-moderate evidence: retrospective clinical study with reasonable sample size but lacking randomization blinding and detailed outcome data.
When this study was published
Published 2021. Sex-specific immune responses to COVID-19 treatments have been further studied as the pandemic evolved.
The bigger picture
Gender-specific immune responses are increasingly recognized in infectious disease. This study adds Tα1 treatment response to the growing evidence that immune-modulating therapies may need sex-specific dosing and monitoring strategies.
Questions still open
- Should Tα1 dosing be adjusted by sex for COVID-19 or other infections?
- Do the gender differences in Tα1 response apply to non-COVID infections?
- Would higher Tα1 doses better support male COVID-19 immune response?
Common questions
What is thymosin alpha-1?
Why do men and women respond differently to COVID-19 treatment?
Read the original research
Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy.
International immunopharmacology, 90, 107022
Citation
Li, Xin; Liu, Lancong; Yang, Yi; Yang, Xuefeng; Wang, Cencen; Li, Yan; Ge, Yanyan; Shi, Yuxin; Lv, Ping; Zhou, Hua; Luo, Pei; Huang, Shilong. (2021). Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy.. International immunopharmacology, 90, 107022. https://doi.org/10.1016/j.intimp.2020.107022